Recent News

• 05.27.2026 - BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
• 05.12.2026 - BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
• 05.11.2026 - Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
• 05.08.2026 - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 05.07.2026 - BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

Recent Filings

• 05.27.2026 - EX-99.1 EX-99.1
• 05.27.2026 - 8-K Current report
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2026 - 144 Report of proposed sale of securities
• 05.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 144 Report of proposed sale of securities
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors